Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery
ClearPoint Neuro, a global therapy-enabling platform company providing navigation and delivery to the brain, today […]
UCB and Ariceum Therapeutics Sign a Strategic Research Collaboration to Discover New Modalities for the Treatment of Immune-related Diseases and Cancer
Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment […]
Huma and UCB to Provide Digital Health Solution for Myasthenia Gravis
Huma Therapeutics, a leading global digital health company, and UCB, a global biopharmaceutical company, are […]
Aitia and UCB Announce Strategic Drug Discovery Collaboration in Huntington's Disease
UCB, a global biopharmaceutical company, and Aitia, the leader in the application of Causal AI […]
Pheno Therapeutics Announces Worldwide License from UCB to a Novel Program for Neurodegenerative Disease
Pheno Therapeutics, a biotechnology company focused on the discovery and development of small molecule therapeutics […]
- Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration Read more
- Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease Read more
- Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas Read more
- Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases Read more
- Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 Read more